Pacer Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Pacer Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,548	Closed	-$17K	–	1559
2020 Q3	$17K	Buy	+5,548	New	+$17.7K	﹤0.01%	1360
2018 Q4	–	Sell	-12,369	Closed	-$33K	–	1209
2018 Q3	$33K	Buy	+12,369	New	+$30.4K	﹤0.01%	1161
2018 Q1	–	Sell	-3,357	Closed	-$9K	–	1204
2017 Q4	$9K	Buy	+3,357	New	+$10.3K	﹤0.01%	1152

Other funds holding PDLI

SPC

Silver Point Capital Greenwich, Connecticut $1.1B AUM 20.71% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $688M AUM 63.39% 1-Year Est. Return

JBF Capital Aspen, Colorado $764M AUM 24.26% 1-Year Est. Return

Gabelli Funds Rye, New York $15.7B AUM 36.4% 1-Year Est. Return

Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Winton Group London, United Kingdom $3.09B AUM 40.4% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Hancock Whitney Gulfport, Mississippi $6B AUM 34.57% 1-Year Est. Return

Pacer Advisors's PDLI Position: Q4 2020 in Review

Pacer Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 5,548 shares — an estimated $17K sold.

Pacer Advisors first reported a position in PDLI in Q4 2017 and held it in 3 quarters. The position peaked at $33K in Q3 2018. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

Pacer Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
Pacer Advisors sold 5,548 PDL BioPharma, Inc. shares in Q4 2020, an estimated $17K.
Pacer Advisors first reported a position in PDL BioPharma, Inc. in Q4 2017 and held it in 3 quarters.
Pacer Advisors's PDL BioPharma, Inc. position peaked at $33K in Q3 2018.
33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Pacer Advisors's 13F filing for Q4 2020, filed 20 Jan 2021.